# FIGHT-201 (NCT02872714)

> A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201)

No report yet. It can be ordered.

- Drugs tested: pemigatinib
- Indication: metastatic or unresectable urothelial carcinoma with FGF/FGFR alterations

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02872714
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Incyte Corporation
- Conditions: UC (Urothelial Cancer)
- Interventions: pemigatinib; pemigatinib
- Enrollment: 263
- Primary outcome: Objective Response Rate (ORR) in Participants With FGFR3 Mutations or Fusions on a CD Regimen

## Indexed commentary on FIGHT-201 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 6 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=fight-201-nct02872714